Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 474
Filtrar
1.
Integr Med Res ; 11(1): 100776, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34745879

RESUMO

Background: Core outcome sets (COSs) are the minimum outcomes which should be measured and reported by researchers investigating a specific condition. The definition of standards of COSs vary across different health-related areas. This investigated the characteristics of COSs regarding obstetrics and gynecology (OG) and examined the reports and designs of standards of OG COSs. Methods: A comprehensive search was conduced on the COMET database on December 20, 2019 to identify systematic reviews on COSs. Two reviewers independently evaluated whether the reported OG COS met the reporting requirements as stipulated in the Core Outcome Set-STAndards for Reporting (COS-STAR) statement checklist and the minimum design recommendations as outlined in the Core Outcome Set-STAndards for Development (COS-STAD) checklist. Results: Forty-four OG COSs related to 26 topics were identified. None of them met all the 25 standards of COS-STAR statement which representing 18 items considered essential for transparent and complete reporting list for all COS studies (range: 6.0-24.0, median: 14.0). The compliance rates to 16 standards of methods and result sections ranged from 27.3%-68.2%. Total COS-STAR compliance items for OG COSs with the prior protocol was significantly higher than without prior protocol (MD = 3.846, 95% CI: 0.835-6.858, P = 0.012). None of the OG COSs met all the 12 criteria in the COS-STAD minimum standards (range: 3.0-11.0, median: 5.0). The compliance rates for all three standards of stakeholders involved and all four standards of the consensus process were lower than 60%. Conclusions: Methodological and reporting standards of OG COSs should be improved.

2.
Chin J Integr Med ; 2021 Nov 24.
Artigo em Inglês | MEDLINE | ID: mdl-34816364

RESUMO

OBJECTIVE: To evaluate whether skin tests are suitable to predict the allergy reactions induced by Chinese herbal injections (CHIs). METHODS: The skin tests including skin prick tests (SPT), intradermal tests (IDT) and provocation tests including subcutaneous tests and intravenous tests were administered to 249 healthy subjects and 180 allergic patients for 3 CHIs, including ginkgolide injection, diterpene ginkgolide meglumine injection and Salvianolate lyophilized injection. The results of the provocation tests were used as the "gold standard" to determine the sensitivity and specificity of the skin tests. RESULTS: The results did not show any significant differences between the healthy and allergy groups in both skin tests and provocation tests (P>0.05). The specificities of SPT and IDT were 0.976 and 0.797, respectively, and the sensitivities of both SPT and IDT were 0. CONCLUSION: Skin tests are insufficient to predict the likelihood of allergic reactions resulting from CHIs. (ChiCTR-CPC-15006921).

3.
Bioresour Technol ; 344(Pt B): 126262, 2021 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-34728360

RESUMO

This study investigated the effects of pretreatment using an acetone-butanol-ethanol (ABE) mixture with and without H2SO4 (H+) as a catalyst on sugar recovery from Salix schwerinii biomass. The sugar recovery was susceptible to both the temperature and the catalyst. Moreover, the relatively higher concentration of ABE (H+ABE4) at 200 °C yielded glucose recovery of 85.5% from the pretreated solid, higher than the recovery under other conditions. This result was mainly attributed to the compositional changes in the biomass, as the xylan and lignin were removed in large quantities by ABE pretreatment at 200 °C. Correspondingly, xylose recovery of 53.8% and glucose recovery of 12.1% were obtained from the liquid in which more sugar degradation products were formed. Ultimately, a fermentation broth containing a low concentration of ABE was successfully employed for pretreatment and showed great potential in producing fermentable sugars from S. schwerinii for biobutanol production.

4.
Zhongguo Zhen Jiu ; 41(11): 1283-90, 2021 Nov 12.
Artigo em Chinês | MEDLINE | ID: mdl-34762385

RESUMO

By searching the randomized controlled trials (RCTs) of acupuncture and moxibustion from CNKI since its inception date to december 31 of 2019, the development status and hot trend of RCTs of acupuncture and moxibustion in China were summarized. The CiteSpace and VOSviewer software were used to perform keyword co-occurrence analysis, clustering analysis, time-zone analysis and citation-burst analysis, and visual map was drawn. As a result, a total of 60 995 articles were included, which were published in 1027 academic journals with 1787 keywords. The publication date was from 1975 to 2019. During the past 45 years, the publications of RCTs on acupuncture and moxibustion had shown an overall growth trend with characteristics of the times. The RCTs of manual acupuncture ranked the top, and its proportion of publications every 5 years was stable in the past 30 years. Since 1994, the hot words such as electroacupuncture, warming needling, auricular point sticking and various acupoint therapies had emerged; meanwhile, the spectrum of diseases had broadened, and an evolutionary trend corresponding to therapies and disease systems had been formed. In recent decade, the RCTs using moxibustion therapy have increased significantly, and the hot words such as "sub-health" "winter diseases being treated in summer" and "acupoint application/ moxibustion during the dog days" had indicated that acupuncture clinical research was further inclined to the field of chronic disease prevention and health services, which was in line with social development and the needs of the times.


Assuntos
Terapia por Acupuntura , Acupuntura , Moxibustão , Pontos de Acupuntura , Ensaios Clínicos Controlados Aleatórios como Assunto
5.
Zhongguo Zhong Yao Za Zhi ; 46(20): 5418-5427, 2021 Oct.
Artigo em Chinês | MEDLINE | ID: mdl-34738445

RESUMO

To systematically review the efficacy and safety of Yangxin Dingji Capsules in the treatment of arrhythmia. PubMed, EMbase, Cochrane Library, CNKI, VIP, CBM and Wanfang databases were electronically retrieved to collect randomized controlled trial(RCT) on the efficacy of Yangxin Dingji Capsules in the treatment of arrhythmia from the time of database establishment to October 20 th, 2020. Two reviewers independently screened out the literatures, input the data, and evaluated the literature quality of the included studies. RevMan 5.3 software was used for Meta-analysis. A total of 127 studies were retrieved, and 15 articles were included after screening, involving 1 371 cases, with 685 cases in the treatment group and 686 cases in the control group. Yangxin Dingji Capsules combined with anti-arrhythmia western medicine was adopted for intervention in the treatment group, while the patients in the control group were treated with the anti-arrhythmia western medicine alone. Meta-analysis results showed that in arrhythmia patients, the combination of Yangxin Dingji Capsules and conventional western medicine significantly increased the clinical efficacy(RR=1.23, 95%CI[1.17, 1.30], P<0.000 01)and left ventricular ejection fraction(MD=4.31, 95%CI[3.10, 5.52], P<0.000 01), reduced heart rate(MD=-3.79, 95%CI[-7.42,-0.15], P=0.04), left ventricular end-diastolic diameter(MD=-7.06, 95%CI[-11.91,-2.21],P=0.004), left ventricular end-systolic diameter(MD=-4.78, 95%CI[-6.63,-2.93],P<0.000 01), N-terminal B-type natriuretic peptide precursor(MD=-200.51, 95%CI[-254.52,-146.51], P<0.000 01)and high-sensitivity C-reactive protein(MD=-1.74, 95%CI[-3.23,-0.24], P=0.02), all with statistically significant differences. Compared with the control group, Yangxin Dingji Capsules had fewer adverse reactions(RR=0.53, 95%CI[0.36, 0.79], P=0.002). The existing evidences showed that Yangxin Dingji Capsules had certain effect in the treatment of arrhythmia, with a safety. However, due to the limitation in sample size, outcome measures and quality of the included studies, more high-quality studies are required to verify the above conclusion.


Assuntos
Medicamentos de Ervas Chinesas , Bradicardia , Cápsulas , Humanos , Volume Sistólico , Função Ventricular Esquerda
6.
Front Pharmacol ; 12: 740821, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34744724

RESUMO

Background: Hypertension, a risk factor for cardiovascular events, is often associated with chronic kidney disease. This is called hypertensive nephropathy (HN), which negatively affects physical fitness and body mass, leading to economic burden. Traditional Chinese medicine injections (TCMIs) are common traditional Chinese-patent medicine preparations in China. There was a lack of evidence to prove which TCMIs combine with ADs (TCMIs+ADs) may be a therapeutic option for HN. Thus, we systematically reviewed the efficacy and safety of various TCMIs + ADs in patients with HN. Methods: We conducted a comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, and VIP information resource integration service platform databases for relevant Chinese- and English-language randomized controlled trials (RCTs) published from database inception until May 2021. Literature screening, data extraction, and quality assessment was performed by two reviewers independently but using the same criteria. We performed the effect modeling to analyze the data for all outcomes and ranked each intervention using the P-score. Furthermore, sensitivity analysis, meta-regression, and funnel plots were used to test the stability, heterogeneity, and publication bias, respectively. Results: We included 69 RCTs with 6373 patients and including six TCMIs + ADs. Network analysis indicated that the ginkgo leaf extract and dipyridamole combined with ADs (GLED + ADs) was the most efficacious in terms of 24-h urinary protein excretion [mean difference (MD) = -0.70, 95% confidence interval (CI): -0.82 to -0.58; P-score = 1] and systolic blood pressure (MD = -12.95, 95% CI: -21.03 to -4.88; P-score = 0.88), whereas the salvianolate combined with ADs (SA + ADs) showed the highest effectiveness for diastolic blood pressure (MD = -6.88, 95% CI: -10.55 to -3.21; P-score = 0.9). Based on the combined P-score of network meta-analysis results (88% and 85.26%) and sensitivity analysis results (72% and 71.54%), the biplots showed that the GLED + ADs was the most efficacious intervention in all TCMIs + ADs for primary outcomes, followed by the SA + ADs and sodium tanshinone IIA sulfonate combined with ADs (STS + ADs). There was no significant difference in terms of safety between TCMIs + ADs and ADs alone. Conclusion: Of all the TCMIs + ADs, GLED + ADs, SA + ADs, and STS + ADs may demonstrate a higher efficacy than ADs alone for HN. Weighing with the potential benefits and limitations in methodology, potential heterogeneity and outcomes, we should use various TCMIs with caution in clinical practice. Nevertheless, additional high-quality RCTs are warranted and future research should focus on the clinical value of core outcomes to confirm the effectiveness and safety of TCMIs for HN. Systematic Review Registration: clinicaltrials.gov, identifier CRD42020205358.

7.
Artigo em Inglês | MEDLINE | ID: mdl-34729244

RESUMO

Traditional Chinese medicine (TCM) has been successfully applied worldwide in the treatment of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the pharmacological mechanisms underlying this success remain unclear. Hence, the aim of this review is to combine pharmacological assays based on the theory of TCM in order to elucidate the potential signaling pathways, targets, active compounds, and formulas of herbs that are involved in the TCM treatment of COVID-19, which exhibits combatting viral infections, immune regulation, and amelioration of lung injury and fibrosis. Extensive reports on target screening are elucidated using virtual prediction via docking analysis or network pharmacology based on existing data. The results of these reports indicate that an intricate regulatory mechanism is involved in the pathogenesis of COVID-19. Therefore, more pharmacological research on the natural herbs used in TCM should be conducted in order to determine the association between TCM and COVID-19 and account for the observed therapeutic effects of TCM against COVID-19.

8.
J Biochem Mol Toxicol ; : e22921, 2021 Oct 04.
Artigo em Inglês | MEDLINE | ID: mdl-34605103

RESUMO

LINC01410 is a tumor promoter that is upregulated in some cancer types, such as osteosarcoma (OS). Nonetheless, its role in OS and the underlying molecular mechanism have not been fully understood. Hence, we sought to elucidate it. We performed reverse-transcription quantitative polymerase chain reaction for examining LINC01410, miR-497-5p and HMGA2 levels. Additionally, we carried out the cell counting kit-8 and Transwell assays for detecting cell proliferation and invasion/migration. Bioinformatics predicted that there was a miR-497-5p binding site in LINC01410 or HMGA2; meanwhile, miR-497-5p was found to interact with HMGA2 and LINC01410 through dual-luciferase reporter assay. LINC01410 and HMGA2 were high, and miR-497-5p showed low expression in OS tissues and cells. Cell function assay demonstrated that LINC01410 or HMGA2 knockdown or miR-497-5p overexpression obviously restrained OS proliferation, invasion, and migration. Oppositely, inhibiting miR-497-5p had the opposite effects. Functionally, miR-497-5p bound with LINC01410 3'-untranslated region and HMGA2 was found to be the miR-497-5p target gene. Lastly, LINC01410 enhanced OS cell growth, invasion, and migration via decreasing miR-497-5p expression, whereas increasing that of HMGA2. We have demonstrated that LINC01410 promoted OS development partly by miR-497-5p/HMGA2 signal transduction pathway and this provides a reference for studying the mechanism of LINC01410 in OS.

9.
J Evid Based Med ; 2021 Oct 11.
Artigo em Inglês | MEDLINE | ID: mdl-34632732

RESUMO

BACKGROUND: The coronavirus disease 2019 (COVID-19) has turned into a pandemic and resulted in huge death tolls and burdens. Integrating Chinese and western medicine has played an important role in the fight against the COVID-19 pandemic. PURPOSE: We aimed to develop a living evidence-based guideline of integrating Chinese and western medicine for COVID-19. STUDY DESIGN: Living evidence-based guideline. METHODS: This living guideline was developed using internationally recognized and accepted guideline standards, dynamically monitoring the release of new clinical evidence, and quickly updating the linked living systematic review, evidence summary tables, and recommendations. Modified Delphi method was used to reach consensus for all recommendations. The certainty of the evidence, resources, and other factors were fully considered, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to rate the certainty of evidence and the strength of recommendations. RESULTS: The first version of this living guidance focuses on patients who are mild or moderate COVID-19. A multidisciplinary guideline development panel was established. Ten clinical questions were identified based on the status of evidence and a face-to-face experts' consensus. Finally, nine recommendations were reached consensus, and were formulated from systematic reviews of the benefits and harms, certainty of evidence, public accessibility, policy supports, feedback on proposed recommendations from multidisciplinary experts, and consensus meetings. CONCLUSION: This guideline panel made nine recommendations, which covered five traditional Chinese medicine (TCM) prescription granules/decoction (MXXFJD, QFPD, XFBD, TJQW, and JWDY), three Chinese patent medicines (LHQW granules/capsule, JHQG granules, and LHQK granules), and one Chinese herbal injection (XBJ injection). Of them, two were strongly recommended (LHQW granules/capsule and QFPD decoction), and five were weakly recommended (MXXFJD decoction, XFBD decoction, JHQG granules, TJQW granules, and JWDY decoction) for the treatment of mild and moderate COVID-19; two were weakly recommended against (XBJ injection and LHQK granules) the treatment of mild and moderate COVID-19. The users of this living guideline are most likely to be clinicians, patients, governments, ministries, and health administrators.

10.
Biomed Pharmacother ; 143: 112238, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34649362

RESUMO

OBJECTIVE: To gain a deeper understanding of the hot topics and future prospects of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors treatment of cancer through scientometric analysis of the top-100 most cited clinical trials. MATERIALS AND METHODS: We searched the Web of Science Core Collection database from 1980 to June 2019. Two reviewers independently screened the top-100 most cited clinical trials that defined by the National Institutes of Health starting from the most cited article. Title, year of publication, citations, type of cancer, and focused aspects of outcomes were extracted from included clinical trials. VOSviewer software (version 1.6.9) and Excel 2016 were used to do statistical analysis. The evidence mapping was used to present the relationship between cancers, drugs, citations, and outcomes, etc. RESULTS: The top-100 most cited clinical trials published from 2010 to 2018 in nine journals with high impact factor (IF) (IF2018:6.68-70.67), and Lancet Oncology (USA) published the most clinical trials (n = 29, IF2018 = 35.3856). The total number of citations of the top-100 most cited clinical trials was from 59 to 5606. 920 authors from 34 countries and 458 organizations participated in publishing the top-100 most cited clinical trials. The USA (n = 95) and Memorial Sloan-Kettering Cancer Center (n = 31) contributed the most publications. Based on the evidence mapping, there are 25 different types of cancers (e.g. lung cancer, melanoma, and renal cell cancer) and five focused aspects of outcomes (e.g. safety and efficacy). CONCLUSION: The USA was the dominant country. Anti-PD-1/PD-L1 drugs were widely used to treat lung cancer, melanoma, renal cell cancer, and Hodgkin lymphoma. More exploration should be done to explore the use of anti-PD-1/PD-L1 drugs to treat more type of cancers in future research.

11.
Bioresour Technol ; 342: 125943, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34547710

RESUMO

Recently, xylo-oligosaccharides (XOS) production from lignocelluloses by organic acid catalysis has been widely reported. However, the effect of delignification of lignocelluloses on XOS production by organic acid catalysis was unclear, and lactic acid (LA) catalysis in XOS production from lignocelluloses has not been reported. In this work, the effect of delignification on XOS production from poplar by LA catalysis was investigated. Results demonstrated that hydrogen peroxide-acetic acid (HPAA) pretreatment removed 83.2% of lignin and retained 95.4% of xylan. After 2% LA catalysis (170 °C, 30 min), a high XOS yield of 42.7% was obtained from HPAA1-LA-pretreated poplar. Lignin removal from poplar was positively correlated with XOS yield. Glucose yield of HPAA1-LA-pretreated poplar by cellulase was 88.9%. Compared with LA-catalyzed poplar, the XOS and glucose production from HPAA1-LA-pretreated poplar by cellulase increased by 1.4-fold and 6.8-fold, respectively. This work presents a novel strategy for efficient producing XOS and monosaccharides from poplar.

12.
Bioresour Technol ; 342: 125979, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34571332

RESUMO

At present, xylooligosaccharides (XOS) from corncob using acid-base conjugate system has not been reported. In this study, XOS production from corncob by two-step acetic acid/sodium acetate (AC/SA) conjugate system hydrolysis and xylanase hydrolysis was optimized, and monosaccharides were subsequently produced from corncob residues by cellulase hydrolysis. The XOS of 19.9 g/L was obtained from corncob (10%, w/v) using 0.15 M AC/SA hydrolysis at a molar ratio of 3.0 at 170 °C for 60 min, followed by xylanase hydrolysis. The second-step AC/SA hydrolysis of hydrolyzed corncob (10%, w/v) produced 3.1 g/L of XOS. Finally, the maximum XOS yield of 74.8% (based on xylan in corncob) was achieved, which is the highest yield among yields reported previously. The purity of XOS was high, whereas the contents of by-products were very low. This work presents a novel and promising strategy for co-production of XOS and monosaccharides from corncob without xylan isolation and purification.

13.
Bioresour Technol ; 342: 125680, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34583110

RESUMO

Xylooligosaccharides (XOS) are usually produced by xylan isolation from lignocellulose by alkaline followed by enzymatic hydrolysis, but the process is complicated. Recently acid hydrolysis for XOS preparation has become popular as it is faster and easier. This study investigated a novel strategy for producing XOS from corncob using propionic acid (PA) hydrolysis, then producing monosaccharides from solid residues by cellulase hydrolysis. The effect of alkaline post-treatment on enzymatic hydrolysis was studied. The maximum XOS yield of 68.5% was achieved using 5% PA at 170 °C for 50 min. About 84% of lignin in PA-hydrolyzed corncob was removed using alkaline post-treatment. The yields of glucose and xylose reached 89.8% and 80.1%, respectively, using 5 FPU cellulase/g dry matter. The results indicated that alkaline post-treatment reduced 50% cellulase loading and improved the saccharification of PA-hydrolyzed corncob. This study presents an innovative option for efficient production of XOS and monosaccharides from corncob.

14.
Acta Pharm Sin B ; 11(11): 3337-3363, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34567957

RESUMO

COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread across the globe, posing an enormous threat to public health and safety. Traditional Chinese medicine (TCM), in combination with Western medicine (WM), has made important and lasting contributions in the battle against COVID-19. In this review, updated clinical effects and potential mechanisms of TCM, presented in newly recognized three distinct phases of the disease, are summarized and discussed. By integrating the available clinical and preclinical evidence, the efficacies and underlying mechanisms of TCM on COVID-19, including the highly recommended three Chinese patent medicines and three Chinese medicine formulas, are described in a panorama. We hope that this comprehensive review not only provides a reference for health care professionals and the public to recognize the significant contributions of TCM for COVID-19, but also serves as an evidence-based in-depth summary and analysis to facilitate understanding the true scientific value of TCM.

15.
Zhongguo Zhong Yao Za Zhi ; 46(15): 4008-4015, 2021 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-34472278

RESUMO

To analyze the outcome indicators from the randomized controlled trials(RCTs) on traditional Chinese medicine(TCM) treatment for diabetic foot, and to lay a foundation for the establishment of the core index set of the clinical trials on TCM treatment of diabetic foot. Computer retrieval of RCTs on TCM treatment of diabetic foot was performed in CNKI, Wanfang, SinoMed, PubMed, Cochrane Library, EMbase and Web of Science databases. Literature screening and data extraction were conducted independently by two researchers in strict accordance with inclusion and exclusion criteria. Any difference was resolved through discussion. A total of 72 RCTs involving 5 791 patients were included and 204 indicators were used. The number of indicators used in a single study was 2-22, with an average of 3 indicators used for each RCT. The indicators with top 16 frequency were clinical total effective rate, ankle brachial index(ABI), ulcer area, TCM syndrome integral, fibrinogen(FIB), fasting blood glucose(FBG), plasma viscosity(PV), c-reactive protein(CRP), saccharification blood of eggs(HbAlc), 2 h postprandial blood glucose(2 hPG), wound healing time, triglyce-rides(TC), TCM efficacy for syndromes, total cholesterol(TG), percutaneous oxygen partial pressure(TCPO2) and TCM symptom scores. The difference in selection of RCT indicators was large among TCM treatment methods for diabetic foot, and the combination of outcome indicators was arbitrary. The description on indexes was not standardized. Some non-laboratory examination indicators, some indicators not recommended in guidelines or not recognized in clinical practice, and some self-made indicators were not explained in detail. There was a lack of standardized evaluation criteria for indicators. The indicators had large time-point difference in measurement, and the time points were not distinguished in the measurement for diabetic foot patients with different degrees of severity. In addition, the patients with long course of treatment weren't timely measured. The characteristics of TCM or significant endpoint indicators were insufficient. It was urgent to establish the core index set of TCM in treating diabetic foot.


Assuntos
Diabetes Mellitus , Pé Diabético , Medicamentos de Ervas Chinesas , Glicemia , Pé Diabético/tratamento farmacológico , Medicamentos de Ervas Chinesas/uso terapêutico , Humanos , Medicina Tradicional Chinesa , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
16.
Chem Sci ; 12(34): 11420-11426, 2021 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-34567496

RESUMO

Divergent synthesis is a powerful strategy for the fast assembly of different molecular scaffolds from identical starting materials. We describe here a solvent-controlled photocatalytic divergent cyclization of alkynyl aldehydes with sulfonyl chlorides for the direct construction of highly functionalized cyclopentenones and dihydropyranols that widely exist in bioactive molecules and natural products. Density functional theory calculations suggest that a unique N,N-dimethylacetamide-assisted 1,2-hydrogen transfer of alkoxy radicals is responsible for the cyclopentenone formation, whereas a C-C cleavage accounts for the selective production of dihydropyranols in acetonitrile and water at 50 °C. Given the simple and mild reaction conditions, excellent functional group compatibility, forming up to four chemical bonds, and tunable selectivity, it may find wide applications in synthetic chemistry.

17.
Am J Transl Res ; 13(8): 9796-9801, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34540112

RESUMO

OBJECTIVE: To explore the clinical effects of the intra-aortic balloon pump (IABP) combined with tirofiban in the treatment of acute myocardial infarction (AMI) and to analyze the combination's influence on patient serum levels. METHOD: 106 patients with AMI admitted to our hospital from February 2017 to February 2018 were recruited as the research cohort. The patients were randomly placed into a control group and an experimental group according to their order of admission, with 53 patients in each group. The patients in the control group were treated with IABP, while the experimental group was treated with IABP combined with tirofiban. The two groups' clinical efficacy and serum levels were compared. RESULTS: The clinical efficacy in the experimental group was significantly higher than the clinical efficacy in the control group. After the treatment, both groups' serum indexes were significantly better, and the experimental group's indexes were comparatively better than the control group's indexes. The experimental group's thrombolysis and thrombin myocardial infarction (TIMI) glow grades were much better than the glow grades in the control group. The experimental group's left ventricular ejection fraction (LVEF) index was higher than the control group', while the left ventricular end-diastolic dimension (LVEDD) index and the left ventricular end-systolic dimension (LVESD) index in the experimental group exhibited lower levels when compared to the control group. The hemorheological parameters in the experimental group were much lower than the hemorheological parameters in the control group, and the difference between the two groups was statistically significant (P < 0.05). CONCLUSION: The clinical effects of an IABP pump combined with tirofiban in treating AMI are significant. The patients' clinical symptoms were alleviated drastically, and their serum levels and cardiac and cardiovascular functions improved significantly. Therefore IABP combined with tirofiban in the treatment of AMI is worthy of clinical application and promotion.

18.
Integr Med Res ; 10: 100774, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34518798

RESUMO

Background: A large number of protocols for Systematic Reviews (SR) of Traditional Chinese Medicine (TCM) for coronavirus disease 2019 (COVID-19) have been registered in the International Prospective Register of Systematic Reviews (PROSPERO). This study aimed to analyze the innovativeness and rigorousness of the SR protocols and make recommendations for the design and implementation of future SRs on TCM for COVID-19. This effort is likely to enhance the value of the produced information and prevent the futility of the research. Methods: PROSPERO was searched comprehensively for identifying SRs of TCM for COVID-19 from the inception of the database to August 2020. Two researchers independently screened the literature, extracted the data, and cross-checked the retrieved information for consistency. The following details were recorded: database, registration time, organizations, types of research included, participants, interventions, and outcome measures. All extracted data were analyzed by an overview. The "P - participants, I - interventions, C - controls, and O - outcomes (PICO)" included in the protocols were compared for similarity. The outcomes of the included SR protocols were compared with the newly published Core Outcome Sets (COSs). Results: A total of 80 protocols of SR related to TCM for COVID-19 were obtained after a primary search, and finally 71 protocols were included. The majority of the protocols were from China. Thirty-two organizations participated in the protocol registrations, including 11 hospitals and 21 universities/colleges. However, some protocols were not innovative or rigorous enough, as the PICO of some protocols were similar and non-specific, and the searched literature was incomprehensive. In addition, COS is not commonly adopted. Conclusions: Registering a protocol of SR is an effective way to ensure the usefulness of the produced information, and to avoid the duplication of research and the wastage of resources. In future SR protocols, it is important to focus on and solve the methodological problems such as non-specific PICO, incomprehensive literature retrieval, and improper outcome measures.

19.
Am J Transl Res ; 13(7): 7906-7913, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34377269

RESUMO

OBJECTIVE: This research was designed to investigate the efficacy of metoprolol combined with nicorandil on unstable angina pectoris (UAP). METHODS: Totally 174 UAP patients treated in the Laixi City People's Hospital from May 2017 to December 2019 were taken as the research objects. They were divided into the control (n=79, CG) and joint (n=95) groups (JG). Patients in the CG were treated with metoprolol, while those in the JG were treated with nicorandil. The clinical efficacy, adverse events and inflammatory reactions were observed. RESULTS: The effective rate of the JG was better than that of the CG after treatment. There were no additional adverse reactions, and the incidence of cardiovascular events reduced. The changes of cardiac function manifested that the left ventricular end systolic diameter (LVESD) and left ventricular end diastolic diameter (LVEDD) in the JG were lower than those in the CG, while the left ventricular ejection fraction (LVEF) was higher. In addition, the serum levels of total cholesterol (TC), triglyceride (TG), high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) in the JG were lower than those in the CG. CONCLUSION: Metoprolol combined with nicorandil is effective for UAP patients, which reduces the incidence of cardiovascular adverse events and inhibits inflammatory reactions.

20.
Plants (Basel) ; 10(8)2021 Aug 21.
Artigo em Inglês | MEDLINE | ID: mdl-34451776

RESUMO

Auxins (IAA) and cytokinins (CKs) are the most influential phytohormones, having multifaceted roles in plants. They are key regulators of plant growth and developmental processes. Additionally, their interplay exerts tight control on plant development and differentiation. Although several reviews have been published detailing the auxin-cytokinin interplay in controlling root growth and differentiation, their roles in the shoot, particularly in leaf morphogenesis are largely unexplored. Recent reports have provided new insights on the roles of these two hormones and their interplay on leaf growth and development. In this review, we focus on the effect of auxins, CKs, and their interactions in regulating leaf morphogenesis. Additionally, the regulatory effects of the auxins and CKs interplay on the phyllotaxy of plants are discussed.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...